These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 31347979)
1. Consideration for Employer-Based and Geographic Attributes Included in Value Assessment Methods of Next-Generation Sequencing Tests. Hart MR; Spencer SJ J Manag Care Spec Pharm; 2019 Aug; 25(8):936-940. PubMed ID: 31347979 [TBL] [Abstract][Full Text] [Related]
2. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487 [TBL] [Abstract][Full Text] [Related]
3. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions. Deverka PA; Douglas MP; Phillips KA Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218 [TBL] [Abstract][Full Text] [Related]
4. Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions. Phillips KA; Deverka PA; Marshall DA; Wordsworth S; Regier DA; Christensen KD; Buchanan J Value Health; 2018 Sep; 21(9):1033-1042. PubMed ID: 30224106 [TBL] [Abstract][Full Text] [Related]
6. Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis. Brazzelli M; Aucott L; Aceves-Martins M; Robertson C; Jacobsen E; Imamura M; Poobalan A; Manson P; Scotland G; Kaye C; Sawhney S; Boyers D Health Technol Assess; 2022 Jan; 26(7):1-286. PubMed ID: 35115079 [TBL] [Abstract][Full Text] [Related]
7. Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy. Garrison LP; Neumann PJ; Willke RJ J Manag Care Spec Pharm; 2019 Nov; 25(11):1185-1192. PubMed ID: 31663458 [TBL] [Abstract][Full Text] [Related]
8. Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions. Regier DA; Weymann D; Buchanan J; Marshall DA; Wordsworth S Value Health; 2018 Sep; 21(9):1043-1047. PubMed ID: 30224107 [TBL] [Abstract][Full Text] [Related]
9. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention. Okere AN; Ezendu K; Berthe A; Diaby V J Manag Care Spec Pharm; 2018 Feb; 24(2):142-152. PubMed ID: 29384027 [TBL] [Abstract][Full Text] [Related]
10. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review. Allen D; Gillen E; Rixson L JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426 [TBL] [Abstract][Full Text] [Related]
11. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic. Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459 [TBL] [Abstract][Full Text] [Related]
12. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100 [TBL] [Abstract][Full Text] [Related]
13. Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. Gallego CJ; Shirts BH; Bennette CS; Guzauskas G; Amendola LM; Horike-Pyne M; Hisama FM; Pritchard CC; Grady WM; Burke W; Jarvik GP; Veenstra DL J Clin Oncol; 2015 Jun; 33(18):2084-91. PubMed ID: 25940718 [TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma. Li Y; Bare LA; Bender RA; Sninsky JJ; Wilson LS; Devlin JJ; Waldman FM Mol Diagn Ther; 2015 Jun; 19(3):169-77. PubMed ID: 25926090 [TBL] [Abstract][Full Text] [Related]
16. Payer perceptions on the use of economic models in oncology decision making. Biskupiak J; Oderda G; Brixner D; Burgoyne D; Arondekar B; Niyazov A J Manag Care Spec Pharm; 2021 Nov; 27(11):1560-1567. PubMed ID: 34714111 [No Abstract] [Full Text] [Related]
17. Generalisability in economic evaluation studies in healthcare: a review and case studies. Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis. Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102 [TBL] [Abstract][Full Text] [Related]
19. Surgical treatments for women with stress urinary incontinence: the ESTER systematic review and economic evaluation. Brazzelli M; Javanbakht M; Imamura M; Hudson J; Moloney E; Becker F; Wallace S; Omar MI; Shimonovich M; MacLennan G; Ternent L; Vale L; Montgomery I; Mackie P; Saraswat L; Monga A; Craig D Health Technol Assess; 2019 Mar; 23(14):1-306. PubMed ID: 30929658 [TBL] [Abstract][Full Text] [Related]